Top

Molecular Cancer

Published in:

Open Access 01-12-2016 | Research

Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death

Authors: Dave J. Augeri, Elaine Langenfeld, Monica Castle, John A. Gilleran, John Langenfeld

Published in: Molecular Cancer | Issue 1/2016

Abstract

Background

Bone morphogenetic proteins (BMP) are embryonic proteins that are part of the transforming growth factor (TGFβ) superfamily, which are aberrantly expressed in many carcinomas. Inhibition of BMP receptors with small molecule inhibitors decreases growth and induces death of lung cancer cells, which involves the downregulation of Id1 and Id3 by a Smad dependent mechanism. Developmentally, BMP and TGFβ signaling utilizes Smad-1/5 independent mechanisms to stabilize the expression of X-linked inhibitor of apoptosis protein (XIAP) and activate TGFβ activated kinase 1 (TAK1), which are known to be potent inhibitors of apoptosis. The role of BMP signaling in regulating XIAP and TAK1 in cancer cells is poorly understood. Furthermore, the interaction between the BMP and TGFβ signaling cascades in regulating the activation of TAK1 in cancer cells has not been elucidated.

Methods

Feedback regulation between the BMP and TGFβ signaling pathways and their regulation of XIAP, TAK1, and Id1 were examined in lung cancer cells utilizing siRNA and inhibitors targeting BMP type I receptors, inhibitors of BMP and TGFβ type I receptors, and an inhibitor of BMP and TGFβ type I and type II receptors.

Results

We show that upon inhibition of BMP signaling in lung cancer cells, the TGFβ signaling cascade is activated. Both the BMP and TGFβ pathways activate TAK1, which then increases the expression of Id1. Inhibition of TGFβ signaling increased Id1 expression except when BMP signaling is suppressed, which then causes a dose-related decrease in the expression of Id1. Inhibition of both BMP and TGFβ signaling enhances the downregulation of TAK1. Our data also suggests that the blockade of the BMP type II receptor enhances the downregulation XIAP, which is important in decreasing the activity of TAK1. Knockdown studies demonstrate that both XIAP and TAK1 regulate the survival of lung cancer cells.

Conclusions

This paper highlights that targeting the BMP and TGFβ type I and type II receptors causes a downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells. Small molecule inhibitors targeting the BMP and TGFβ receptors represents a potential novel means to treat cancer patients.

Available only for authorised users

Weaver M, Yingling JM, Dunn NR, Bellusci S, Hogan BL. Bmp signaling regulates proximal-distal differentiation of endoderm in mouse lung development. Development. 1999;126(18):4005–15.PubMed

Sountoulidis A, Stavropoulos A, Giaglis S, Apostolou E, Chuva de Sousa Lopes SM, et al. Activation of the canonical bone morphogenetic protein (BMP) pathway during lung morphogenesis and adult lung tissue repair. PLoS One. 2012;7(8), e41460. Epub 2012 Aug 20.CrossRefPubMedPubMedCentral

Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005;80(3):1028–32.CrossRefPubMed

Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003;24(9):1445–54. Epub 2003 Jun 19.CrossRefPubMed

Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2(3):141–9.PubMed

Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of smad-1/5. Oncogene. 2006;25(5):685–92.CrossRefPubMed

Ye L, Mason MD, Jiang WG. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Front Biosci. 2011;16:865–97.CrossRef

Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN, et al. BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res. 2009;2:4.CrossRefPubMedPubMedCentral

Nickel J, Sebald W, Groppe JC, Mueller TD. Intricacies of BMP receptor assembly. Cytokine Growth Factor Rev. 2009;20(5–6):367–77.CrossRefPubMed

10.

Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science. 2002;296(5573):1646–7.CrossRefPubMed

11.

Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R. Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells. 2002;7(9):949–60.CrossRefPubMed

12.

Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883–91.CrossRefPubMed

13.

Kurooka H, Nakahiro T, Mori K, Sano K, Yokota Y. BMP signaling is responsible for serum-induced Id2 expression. Biochem Biophys Res Commun. 2012;420(2):281–7. doi:10.1016/j.bbrc.2012.02.150. Epub Mar 6.CrossRefPubMed

14.

Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O’Reilly R, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401(6754):670–7.CrossRefPubMed

15.

Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J Biol Chem. 1999;274(28):19838–45.CrossRefPubMed

16.

Langenfeld E, Hong CC, Lanke G, Langenfeld J. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS One. 2013;8(4), e61256. doi:10.1371/journal.pone.0061256. Print 2013.CrossRefPubMedPubMedCentral

17.

Swarbrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A. 2008;105(14):5402–7. Epub 2008 Mar 31.CrossRefPubMedPubMedCentral

18.

Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008;68(7):2250–8.CrossRefPubMed

19.

Tournay O, Benezra R. Transcription of the dominant-negative helix-loop-helix protein Id1 is regulated by a protein complex containing the immediate-early response gene Egr-1. Mol Cell Biol. 1996;16(5):2418–30.CrossRefPubMedPubMedCentral

20.

Gronroos E, Kingston IJ, Ramachandran A, Randall RA, Vizan P, Hill CS. Transforming growth factor beta inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes. Mol Cell Biol. 2012;32(14):2904–16. doi:10.1128/MCB.00231-12. Epub 2012 May 21.CrossRefPubMedPubMedCentral

21.

Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to stress signaling: smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell. 2003;11(4):915–26.CrossRefPubMed

22.

Liang YY, Brunicardi FC, Lin X. Smad3 mediates immediate early induction of Id1 by TGF-beta. Cell Res. 2009;19(1):140–8.CrossRefPubMed

23.

Qi X, Li TG, Hao J, Hu J, Wang J, Simmons H, et al. BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. 2004;101(16):6027–32. Epub 2004 Apr 9.CrossRefPubMedPubMedCentral

24.

Wong WK, Knowles JA, Morse JH. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2005;33(5):438–46. Epub 2005 Jul 7.CrossRefPubMedPubMedCentral

25.

Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo J. 1999;18(1):179–87.CrossRefPubMedPubMedCentral

26.

Liu Z, Shen J, Pu K, Katus HA, Ploger F, Tiefenbacher CP, et al. GDF5 and BMP2 inhibit apoptosis via activation of BMPR2 and subsequent stabilization of XIAP. Biochim Biophys Acta. 2009;1793(12):1819–27. doi:10.1016/j.bbamcr.2009.09.012.CrossRefPubMed

27.

Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, et al. TAK1 is an essential regulator of BMP signalling in cartilage. Embo J. 2009;28(14):2028–41. doi:10.1038/emboj.2009.162. Epub Jun 18.CrossRefPubMedPubMedCentral

28.

Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell Death Differ. 2014;21(11):1667–76. doi:10.1038/cdd.2014.123.CrossRefPubMedPubMedCentral

29.

Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein—a critical death resistance regulator and therapeutic target for personalized cancer therapy. Frontiers in oncology. 2014;4:197. doi:10.3389/fonc.2014.00197.CrossRefPubMedPubMedCentral

30.

Jiao G, Guo W, Ren T, Lu Q, Sun Y, Liang W, et al. BMPR2 inhibition induced apoptosis and autophagy via destabilization of XIAP in human chondrosarcoma cells. Cell death & disease. 2014;5, e1571. doi:10.1038/cddis.2014.540.CrossRef

31.

Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol. 2010;5(2):245–53. doi:10.1021/cb9002865.CrossRefPubMedPubMedCentral

32.

Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008;18(15):4388–92.CrossRefPubMedPubMedCentral

33.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011;2(3):135–64.CrossRefPubMedPubMedCentral

34.

Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J. 2009;28(14):2028–41. doi:10.1038/emboj.2009.162.CrossRefPubMedPubMedCentral

35.

Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013;23(11):3248–52. doi:10.1016/j.bmcl.2013.03.113. Epub Apr 11.CrossRefPubMedPubMedCentral

36.

Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, et al. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem Biol. 2013;8(3):643–50. doi:10.1021/cb3005897. Epub 2013 Jan 7.CrossRefPubMed

37.

Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFβ and BMP pathways. Cell Signal. 2011;23(11):1831–42. doi:10.1016/j.cellsig.2011.06.019. Epub Jun 29.CrossRefPubMed

38.

Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 1999;18(1):179–87. doi:10.1093/emboj/18.1.179.CrossRefPubMedPubMedCentral

39.

Shin H, Okada K, Wilkinson JC, Solomon KM, Duckett CS, Reed JC, et al. Identification of ubiquitination sites on the X-linked inhibitor of apoptosis protein. Biochem J. 2003;373(Pt 3):965–71. doi:10.1042/bj20030583.CrossRefPubMedPubMedCentral

40.

Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008;7(4):829–40. doi:10.1158/1535-7163. mct-07-0337.CrossRefPubMedPubMedCentral

41.

Heinke J, Kerber M, Rahner S, Mnich L, Lassmann S, Helbing T, et al. Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior. Oncogene. 2012;31(24):2919–30. doi:10.1038/onc.2011.473. Epub Oct 24.CrossRefPubMedPubMedCentral

42.

Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol. 1997;17(10):5888–96.CrossRefPubMedPubMedCentral

43.

O’Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell. 2012;21(6):777–92. doi:10.1016/j.ccr.2012.04.036.CrossRefPubMed

44.

Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, et al. TRAF4 promotes TGF-beta receptor signaling and drives breast cancer metastasis. Mol Cell. 2013;51(5):559–72. doi:10.1016/j.molcel.2013.07.014.CrossRefPubMed

45.

Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008;10(10):1199–207. doi:10.1038/ncb1780.CrossRefPubMed

46.

Van Themsche C, Chaudhry P, Leblanc V, Parent S, Asselin E. XIAP gene expression and function is regulated by autocrine and paracrine TGF-beta signaling. Mol Cancer. 2010;9:216. doi:10.1186/1476-4598-9-216.CrossRefPubMedPubMedCentral

47.

Neil JR, Tian M, Schiemann WP. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem. 2009;284(32):21209–17. doi:10.1074/jbc.M109.018374.CrossRefPubMedPubMedCentral

48.

Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 2012;19(1):42–50. doi:10.1038/cdd.2011.121.CrossRefPubMedPubMedCentral

49.

Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656–65. doi:10.1038/cdd.2010.138.CrossRefPubMedPubMedCentral

50.

Cheung HH, St Jean M, Beug ST, Lejmi-Mrad R, LaCasse E, Baird SD, et al. SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. Cell death & disease. 2011;2, e146. doi:10.1038/cddis.2011.25.CrossRef

51.

Peng X, Wang Y, Kolli S, Deng J, Li L, Wang Z, et al. Physical and functional interaction between the ID1 and p65 for activation of NF-kappaB. Am J Physiol Cell Physiol. 2012;303(3):C267–77. doi:10.1152/ajpcell.00365.2011.CrossRefPubMedPubMedCentral

52.

Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-induced transformation involves the activation of mammalian target of rapamycin. Mol Cancer Res. 2005;3(12):679–84.CrossRefPubMed

53.

Leite M, Quinta-Costa M, Leite PS, Guimaraes JE. Critical evaluation of techniques to detect and measure cell death—study in a model of UV radiation of the leukaemic cell line HL60. Anal Cell Pathol. 1999;19(3–4):139–51.CrossRefPubMedPubMedCentral

Title: Inhibition of BMP and of TGFβ receptors downregulates expression of XIAP and TAK1 leading to lung cancer cell death
Authors: Dave J. Augeri
Elaine Langenfeld
Monica Castle
John A. Gilleran
John Langenfeld
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2016
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-016-0511-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Circulating long non-coding RNAs in cancer: current status and future perspectives

MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma

Reciprocal activation between STAT3 and miR-181b regulates the proliferation of esophageal cancer stem-like cells via the CYLD pathway

Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment

Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib

Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer